retatrutide phase 2 trial new england journal of medicine Efficacy and safety retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Retatrutide Helped Adults With Obesity

CrossRef Integrating multi-omics and machine learning systematically deciphers cellular heterogeneity and fibrotic regulatory networks in the progression from MASLD to MASH Weiheng Wen, Zenghui Liu, Wenliang Tan, Yingzheng Tan, Wei Li, Jian Wan, Hongsai Hu, Zhengwu Jiang, Xing Tang, Jing Yang, Jiao Xiao, Xiongjin Tan, Xun Chen, Peili Wu, Yukun Li npj Digital Medicine .2026;[Epub] CrossRef Morphological characterization of a novel model of steatohepatitis in the FAH -/- pig Silvana N

Ovulation Pain

Laboratory Tests for the Assess- ment of Nutritional Status

GLP-1 agonists can trigger acute kidney injury in dehydrated states and pose thyroid considerations

Key Facts GLP-1 receptor agonists are medicines used to treat Type II diabetes and, in some cases, support weight management

Levels of GHK-Cu in the body naturally decline during aging [2]